Affordable Access

deepdyve-link
Publisher Website

The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency.

Authors
  • Livnat, Tami1
  • Shenkman, Boris1
  • Martinowitz, Uri1
  • Zivelin, Ariella2
  • Dardik, Rima1
  • Tamarin, Ilia2
  • Mansharov, Rachel2
  • Budnik, Ivan3
  • Salomon, Ophira4
  • 1 National Hemophilia Center and Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. , (Israel)
  • 2 Coagulation Laboratory, Sheba Medical Center, Tel Hashomer, Israel. , (Israel)
  • 3 Department of Pathophysiology, Sechenov First Moscow State Medical University, Moscow, Russia.
  • 4 National Hemophilia Center and Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: [email protected] , (Israel)
Type
Published Article
Journal
Thrombosis research
Publication Date
Aug 01, 2015
Volume
136
Issue
2
Pages
465–473
Identifiers
DOI: 10.1016/j.thromres.2015.06.025
PMID: 26160656
Source
Medline
Keywords
License
Unknown

Abstract

The phenotype of bleeding in patients with severe FXI deficiency is unpredictable and unlike other bleeding disorders, it is not directly correlated with levels of FXI. In this study we analyzed whether the global coagulation assays can serve as a clinical tool in predicting bleeding tendency in patients with severe FXI deficiency undergoing surgery, taking into account the large inter-individual variability of FXI levels and genotypes. Thrombin generation (TG) was measured in 39 platelet-poor plasma with or without tissue factor (TF) and in the presence or absence of corn trypsin inhibitor (CTI). Rotation thromboelastometry (ROTEM) was performed with fresh whole blood of 26 patients applying NATEM and INTEM tests. TG induced by recalcification can distinguish between bleeding and non-bleeding patients with severe FXI deficiency particularly among those with FXI activity of 2-20IU/dl. The addition of TF or TF and CTI to the TG assay masked the ability to differentiate between XI activity, genotype as well as bleeding and non-bleeding patients. ROTEM assays failed to distinguish bleeding from non-bleeding patients but could do so between different FXI activity levels and genotypes. In conclusion, in the current study we found a sensitive tool to distinguish between bleeding and non-bleeding patients. In order to recommend TG as a predictive tool for treatment tailoring, a larger patient group is required.

Report this publication

Statistics

Seen <100 times